What is the current stock price of Bavarian Nordic A/S (BVNRY)?

As of the latest market data, Bavarian Nordic A/S (BVNRY) is trading at $10.45. The stock has seen a gain of 0.38% today.

Does Bavarian Nordic A/S (BVNRY) pay a dividend?

Based on current data, Bavarian Nordic A/S does not have a confirmed active dividend policy.

What is the market cap of Bavarian Nordic A/S?

The current market capitalization of Bavarian Nordic A/S (BVNRY) is approximately unavailable.

BVNRY

Bavarian Nordic A/S·Healthcare

10.45

0.384%(+0.04)

Market Closed

Last Updated: — ET

52W L: $7.3152W H: $13.00

BVNRY NEWS

globenewswire.com

Mar 24

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on

seekingalpha.com

Mar 12

Bavarian Nordic A/S (BVNRY) Q4 2025 Earnings Call Transcript

globenewswire.com

Mar 12

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 12, 2026 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company's shares/related securities by persons holding managerial responsibilities and/or persons/companies closely associated with such, which are hereby reported in accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523.

globenewswire.com

Feb 12

Bavarian Nordic Reports Preliminary 2025 Financial Results and Provides Guidance for 2026

Exceeding latest 2025 guidance following a strong performance from both commercial arms of the business in Travel Health and Public Preparedness. 2026 guidance reflects continued growth in Travel Health (10% from own products, 14% at constant exchange rates) and a normalized year in Public Preparedness, both in line with the communicated mid-term growth ambitions.

globenewswire.com

Feb 9

Bavarian Nordic – Completion of Share Buy-Back Program

COPENHAGEN, Denmark, February 9, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced and initiated on January 7, 2026, has now been completed, reaching an aggregate amount of approximately DKK 150 million as planned. This represented the first tranche of a total planned share buy-back of up to DKK 500 million in 2026. Bavarian Nordic will hold the shares bought back as treasury stock, for the purpose of adjusting the capital structure.

globenewswire.com

Feb 2

Bavarian Nordic – Transactions in Connection with Share Buy-Back Program

COPENHAGEN, Denmark, February 2, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on January 7, 2026, under which the Company will repurchase shares for an amount up to DKK 150 million in the period from January 7, 2026 to February 13, 2026. The program is executed in accordance with Regulation (EU) No. 596/2014 (as amended) of the European Parliament and of the Council on market abuse and Commission Delegated Regulation (EU) 2016/1052, which together constitute the Safe Harbour Regulation.

Company Profile

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN (freeze-dried) that has completed Phase III clinical trials for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase II clinical trial for the treatment of SARS-CoV-2; and TAEK-VAC, which is in Phase I/II clinical trial for treatment of advanced HER2 and brachyury-expressing cancers. It has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, Japan, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Sector

Healthcare

Industry

Biotechnology

Employees

1,645

IPO Date

2013-04-03

Beta

1.00

Websitewww.bavarian-nordic.com↗